Explore

Mayo Clinic Research Suggests Hormone Therapy Enhances Tirzepatide Weight Loss in Postmenopausal Women

Mayo Clinic Research Suggests Hormone Therapy Enhances Tirzepatide Weight Loss in Postmenopausal Women

New research from the Mayo Clinic indicates that postmenopausal women combining hormone therapy with tirzepatide experienced significantly greater weight loss compared to those using tirzepatide alone. A study involving 120 postmenopausal women with overweight or obesity found that participants receiving both treatments lost an average of 19.2% of their initial body weight, a 35% greater reduction than the 14.0% observed in women using tirzepatide exclusively. Furthermore, 45% of women on combined therapy achieved at least a 20% body weight loss, whereas only 18% of those on tirzepatide alone reached this milestone. Both groups showed improvements in metabolic health, but women on hormone therapy also saw notable reductions in diastolic blood pressure, triglycerides, and the liver enzyme AST. This finding aligns with a previous Mayo Clinic study on semaglutide, suggesting a broader pattern across incretin-based therapies where hormone therapy may create a more favorable metabolic environment.

New Study Links GLP-1 Weight Loss Drugs to Rare Brain Condition

New Study Links GLP-1 Weight Loss Drugs to Rare Brain Condition

A recent Israeli study has identified a potential link between GLP-1 weight loss and diabetes drugs and a rare, serious brain condition called Wernicke encephalopathy. The study, which reviewed U.S. Food and Drug Administration’s adverse event reports and related literature, found 15 cases of Wernicke encephalopathy between 2023 and 2024 in individuals taking these medications. Wernicke encephalopathy is a life-threatening neurological disorder caused by a severe deficiency of vitamin B1, which can lead to permanent memory loss and an inability to form new memories. Experts emphasize that this condition is rare, with only 15 cases identified out of millions of people using GLP-1 drugs. Most of the reported cases involved patients experiencing gastrointestinal side effects such as vomiting, diarrhea, and loss of appetite, which can lead to malnutrition and vitamin B1 deficiency. The majority of these cases were associated with semaglutide-based drugs like Ozempic and Wegovy, or tirzepatide GLP-1s such as Ze...

Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

By Mariam Sunny Sept 14 (Reuters) - Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk with its Wegovy pill.

Wellness Influencers Promote Berberine as "Nature's Ozempic" in the U.S., Despite Traditional Use

Wellness Influencers Promote Berberine as "Nature's Ozempic" in the U.S., Despite Traditional Use

Wellness Influencers Promote Berberine as "Nature's Ozempic" in the U.S., Despite Traditional Use

Arbor's GLP-1 plans start at $99 per month. Get started in 90 seconds

Arbor's GLP-1 plans start at $99 per month. Get started in 90 seconds

Arbor connects eligible patients with licensed providers who can prescribe compounded GLP-1 weight loss medications online. Plans start at $99 per month.

Consistent CPAP Use Linked to Reduced Depression Risk in Long-Term Study

Consistent CPAP Use Linked to Reduced Depression Risk in Long-Term Study

A long-term study conducted in France has found a significant association between consistent use of CPAP (Continuous Positive Airway Pressure) therapy and a lower risk of developing major depressive disorder in individuals with obstructive sleep apnea (OSA). Researchers followed 2,712 CPAP users for a median of approximately 8.5 years. The study compared participants who used CPAP for at least four hours per night with those who used it less consistently. Among those who used CPAP consistently, 19.2% developed depression, compared to 24.2% in the less consistent group. After accounting for various factors such as age, sex, BMI, socioeconomic status, insomnia complaints, and initial depressive symptoms, consistent CPAP use was associated with a 17% lower risk of developing depression. This research suggests that treating OSA consistently may have mental health benefits beyond just improving sleep quality.

Blood Centers Positioned to Scale Cell and Gene Therapies for Biopharma

Blood Centers Positioned to Scale Cell and Gene Therapies for Biopharma

The Blood and Cells Advocacy Roster (BCAR), an industry group, is advocating for biopharmaceutical companies to leverage existing blood center infrastructure to scale cell and gene therapies (CGTs). As CGTs transition from treating small cohorts at academic centers to larger patient populations, a significant bottleneck has emerged in the initial cell collection and delivery process. Historically, this 'first mile' of CGT manufacturing has been handled by clinical research teams at academic medical centers, a model that is proving unscalable, inefficient, and geographically limited for broader commercial use. Blood centers, with their established infrastructure, regulatory compliance, quality systems, and community footprint, are presented as a ready-made solution. They possess experience in leukapheresis, donor recruitment, screening, logistics, and managing cellular starting material for both autologous (patient's own cells) and allogeneic (donor cells) therapies, all under rigorous quality regimes align...

Eric Stonestreet Reveals Significant Weight Loss, Addresses Mounjaro Speculation

Eric Stonestreet Reveals Significant Weight Loss, Addresses Mounjaro Speculation

Eric Stonestreet Reveals Significant Weight Loss, Addresses Mounjaro Speculation

Oregon Health Science University Research Reveals Circadian Rhythm's Role in Nocturnal Blood Pressure Regulation

Oregon Health Science University Research Reveals Circadian Rhythm's Role in Nocturnal Blood Pressure Regulation

Researchers at Oregon Health & Science University, led by Leandro C. Brito, have discovered that the cardiac baroreflex, the body's natural blood pressure stabilizer, is most active during the biological night, specifically when systolic blood pressure reaches its lowest point. This study, published in Physiological Reports, utilized a forced desynchrony protocol on eleven healthy young adults to isolate the internal circadian clock's effect from behavioral influences like sleep and activity. The findings indicate that while baroreflex sensitivity showed no significant circadian variation, the baroreflex effectiveness index peaked around 1 AM, averaging 34% above its mean, and was lowest around 9 AM. This nocturnal peak in effectiveness primarily stemmed from the baroreflex's ability to correct increases in blood pressure, being 110% more effective during the circadian night than in the morning. The study also observed circadian rhythms in vascular function, with brachial artery vascular conductance peakin...

Sesame Care Offers Marketplace Model for GLP-1 Treatments with Variable Pricing

Sesame Care Offers Marketplace Model for GLP-1 Treatments with Variable Pricing

Sesame Care operates as a marketplace that connects patients with independent clinicians for various healthcare needs, including GLP-1 treatments. Unlike many other programs that publish standardized medication pricing, Sesame Care's model means that visit and program fees, as well as medication costs, vary by the individual provider selected and the patient's location. Consequently, patients do not find a stable, all-inclusive medication price publicly listed. Instead, they must request an individualized quote after going through an intake process and selecting a provider. This approach contrasts with seven verified alternative programs that offer transparent, month-to-month rates, such as PlexusDx, which provides compounded semaglutide injection for $189 monthly and compounded tirzepatide injection for $289 monthly, without a membership fee. Other alternatives like Eden offer slightly higher all-in costs but still maintain published rates.

Intermittent Fasting Shows Promise for Type 1 Diabetes Management in Small Trial

Intermittent Fasting Shows Promise for Type 1 Diabetes Management in Small Trial

A new randomized trial has investigated the effects of time-restricted eating, a form of intermittent fasting, in adults with type 1 diabetes who are also overweight or obese. The study, which involved 32 participants, assigned individuals to one of three groups for six months: an eight-hour eating window (noon to 8 p.m.) without calorie counting, a daily 25% calorie reduction, or no dietary intervention. The findings indicated that the time-restricted eating group experienced an improvement in HbA1c levels compared to the calorie-restriction group, specifically a reduction of approximately 0.46 percentage points. Crucially, this group did not report an increase in severe hypoglycemia, hyperglycemia, or diabetic ketoacidosis, which are significant safety concerns for individuals managing type 1 diabetes. While the study suggests potential benefits for glucose control, researchers emphasize that this was a small, supervised trial and does not constitute a recommendation for individuals with type 1 diabetes ...

Strength Training Surpasses Weight Loss as Primary Fitness Goal Amidst GLP-1 Medication Rise

Strength Training Surpasses Weight Loss as Primary Fitness Goal Amidst GLP-1 Medication Rise

Strength Training Surpasses Weight Loss as Primary Fitness Goal Amidst GLP-1 Medication Rise